© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ozagrel methyl ester traces its origin back to the late 20th century, a period bubbling with new discoveries in vascular pharmacology. Japanese researchers, focusing on thromboxane A2 inhibition, first zeroed in on ozagrel itself as an antidote to unwanted platelet aggregation and vascular constriction. Methylation followed as chemists experimented to tweak ozagrel’s pharmacokinetic properties, pushing for derivatives that offered greater solubility, stability, and bioavailability. Insights from the early studies demonstrated that methyl esterification delivered molecules with enhanced drug-likeness, a theme that continues to steer research today.
The methyl ester of ozagrel lives in a league of its own among thromboxane synthase inhibitors. It appears as an off-white crystalline powder, destined for use in biochemical research and the pharmaceutical industry. While its parent compound made waves as an anti-thrombotic agent, the methyl ester stands apart due to better membrane permeability. Scientists handling this molecule see a compound keen to blend performance in vitro with promises for in vivo application, where many former analogs have failed.
Ozagrel methyl ester stands out not just for its crisp crystalline appearance but also for physical properties harnessed to medicinal chemistry’s demands. With a molecular weight slightly higher than ozagrel due to the ester group, it dissolves readily in polar organic solvents but resists dissolution in water. The esterification process imparts a slight increase in lipophilicity—an important attribute for crossing cellular barriers. Its melting point requires careful monitoring; overheating can trigger decomposition, so handling must stay precise. A moderate pKa ensures its stability across physiological pH ranges, and chemists appreciate the chemical’s resistance to hydrolysis under ambient handling conditions.
Labs require tight, reliable specs for ozagrel methyl ester to ensure consistency batch after batch. Purity usually sits above 98%, confirmed through HPLC analysis. Labels list CAS number, storage conditions—cool and dry, shielded from light—and batch results for elemental analysis and moisture. Packaging ranges from amber glass to tightly sealed plastic, all aimed to keep moisture and air at bay. Each shipment includes a certificate of analysis detailing impurity profiles, specific rotation, and spectroscopic fingerprints, aligning with both industry regulations and the confidence benchmarks experts expect for work in pharmaceutical development.
Producing ozagrel methyl ester starts from ozagrel, using classic Fischer esterification. Chemists dissolve ozagrel in anhydrous methanol, add a strong acid catalyst—often sulfuric acid—and warm the mixture gently. After hours’ long stirring, neutralization with sodium bicarbonate follows, and the organic layer is washed, dried, and concentrated under reduced pressure. Column chromatography often helps isolate the pure ester, and NMR spectroscopy then confirms the structure. This process demands both skill and patience, balancing temperature and solvent volumes to chase a top yield and spotless purity.
Ozagrel methyl ester acts as a starting point for inventive chemistry. Researchers have explored modifications to its aromatic ring, substitutions on the ester group, and diverse salt formations—all seeking improved drug profiles. Hydrogenation of double bonds, halogenation for metabolic resistance, and conjugation with targeting ligands become possible, thanks to the accessible ester moiety. This flexibility opens doors to prodrug strategies, aiming to improve half-life or tissue targeting. My own work in medicinal chemistry taught me that small tweaks—swapping a methyl for an ethyl, say—can sometimes spell the difference between a lab curiosity and a breakthrough therapy.
Outside the sterile world of scientific catalogs, ozagrel methyl ester wears several hats. Some suppliers roll with names like "Ozagrel methylate" or "Methyl ozagrelate." It sometimes appears under code numbers in clinical or preclinical documentation. All trademarks and branding follow regional pharmaceutical and chemical registry rules, helping those working with derivatives or related compounds track sourcing and safety information without missing a beat.
Lab safety teams deal with ozagrel methyl ester using trusted protocols. Skin, eye, and respiratory protection guard staff against the irritation some users report. Fume hood work limits inhalation risk, and material safety data sheets flag both acute risks and chronic exposure potential. Disposal requires incineration or collection by chemical waste firms, avoiding drain or landfill entry. Regulatory frameworks scattered across jurisdictions—REACH in Europe, TSCA in the US, and local registries—set rules for use, storage, and reporting. Training and reminders about proper handling form a regular part of lab onboarding, a lesson learned through experience when mislabeling once led to a close call in my own team.
Ozagrel methyl ester holds value for fields hunting better ways to control blood clots and vascular spasms. It enters the spotlight in pharmacological research aimed at stroke, heart attack, and complications from diabetes, adding a new angle to studies on thromboxane A2’s influence over platelet function and inflammation. The esterified form draws the interest of those designing delivery strategies—patches, oral tablets, and targeted nanoparticles—hoping to bypass the headaches from bulkier, less-penetratative molecules. Clinical trials may lag behind, but in animal studies it has sparked hope for therapies that manage platelet activity without the bleeding risks heavy in established agents like aspirin or warfarin.
Ozagrel methyl ester’s story keeps gaining pages in the R&D notebooks of firms and academic labs around the globe. Preclinical studies increasingly probe its influence on vascular smooth muscle, platelet aggregation, and inflammatory cascades, using cell cultures and animal models. Collaboration stands out: chemists partner with pharmacologists, and industry teams link up with academic centers to chase both theory and practical application. Structure-activity relationship mapping and computer-aided drug design feature prominently, matching what I’ve seen in my own stints with pharmaceutical companies, where libraries of derivatives grew by the month on the search for potent, safe compounds. R&D’s next phase will hinge on cleaner, greener synthesis, tighter impurity profiles, and methods to lower cost without sacrificing integrity.
Any new compound aiming for medical use must clear the toxicity hurdle, and ozagrel methyl ester gets no free pass here. Studies dig deep into acute, sub-chronic, and chronic effects, keeping an eye on liver, kidney, and cardiovascular impact. The methyl ester has performed reasonably well in rodent studies, with dose-related changes noted but few outright red flags. As I’ve seen in laboratory settings, surprises can crop up—sometimes even a promising compound triggers rare hypersensitivity or off-target metabolic reactions. Toxicologists aim to pin down not just safe dose ranges but also metabolic breakdown products, since these sometimes signal problems lurking below the surface.
Looking ahead, ozagrel methyl ester offers promise for both therapy and science. Drug developers fix their gaze on improved oral agents for stroke and clot prevention, and researchers in inflammation and rare vascular diseases see further unexplored ground. Prodrug strategies anchored on this ester push possibilities into the realm of tissue targeting and long-acting formulations, dangling the prospect of fewer side effects and more precise control. The challenge will rest on proving in robust clinical trials that theoretical advantages translate into real patient benefits. Regulatory agencies and patients alike demand evidence, not just promise. To get there, continued investment in clean synthesis, richer safety datasets, and cross-border regulatory harmonization will shape the way forward.
Ozagrel methyl ester often turns up when researchers and doctors look for new ways to control blood clots and inflammation. The active part of the molecule, ozagrel, blocks something called thromboxane synthase. Thromboxane helps blood cells clot and makes blood vessels tighten up, both big players in heart attack and stroke. By blocking this step, ozagrel methyl ester lowers the chances of unwanted clots, especially in those with heart disease or after certain surgeries. It helps prevent blood from sticking together too much. This brings real hope for folks who are at risk but can’t tolerate older blood thinners.
As someone who’s seen what unchecked clotting can do, from a grandparent’s stroke to neighbors coming home from heart surgery, blood thinners change outcomes. Traditional medications like aspirin or warfarin still dominate, but not everyone does well on them. Side effects or other illnesses often force doctors to keep searching. In labs and early-stage trials, ozagrel methyl ester and similar drugs open new paths for people who don’t fit into the old categories.
Cardiovascular disease claims more lives globally than anything else. The World Health Organization puts heart disease at the very top of its list. Safe, effective ways to keep blood moving mean fewer hospital visits, less disability, and longer lives at home. Ozagrel methyl ester isn’t some magic bullet, but it moves us closer to that target. It brings another option into the toolkit when others don’t work. For families who’ve seen what a stroke can take away, that’s not a small thing.
Inflammation shows up in so many diseases, from arthritis to brain injuries. Some early research points to ozagrel’s impact beyond just clotting—possibly cooling off harmful inflammation in blood vessels or the brain. Animal studies have looked at conditions like spinal cord injury and cerebral infarction. Feedback from those pilots should shape the next wave of clinical trials. More work lies ahead, but these hints point to future treatments for both blood flow and inflammatory problems.
New drugs rarely get a clear road. Ozagrel methyl ester still faces hurdles: showing it works better than current drugs, proving long-term safety, and tackling cost. Some trials show promise, but much of the world’s data still comes from Japan and China. To build trust, we need more work across different backgrounds, ages, and health systems. Strong evidence, published in recognized journals and backed by thoughtful peer review, helps patients and doctors judge the facts for themselves.
Getting this research out in the open matters most. Patients benefit when multiple universities and hospitals share results without hiding the risks. Advocacy groups can work with researchers to recruit more diverse participants in trials. Companies, doctors, and regulatory agencies need to keep transparency front and center, sharing what works and what falls short honestly. Only by bringing these voices together can promising drugs like ozagrel methyl ester move from curiosity to trusted part of care.
Deciding to use any medicine usually brings a mix of hope and caution. Ozagrel Methyl Ester falls into the class of antiplatelet agents, designed for people dealing with blood clot risks. Having lived with family members on blood thinners after strokes, I’ve seen the rollercoaster of relief and worry. Sure, the goal is to prevent dangerous clots, but every pill comes with a trade-off. Knowing about side effects arms us with information, letting us spot trouble before it gets serious.
Ozagrel Methyl Ester acts on blood platelets, so the most obvious risk is bleeding. That doesn’t just show up as cuts that take too long to scab over. It can mean gums that bleed during brushing, unexplained bruising, or nosebleeds that seem to come out of nowhere. I remember my dad’s confusion when he started getting purple spots on his arms, long after switching to an antiplatelet—turns out, it was related to the medication, not aging or clumsiness.
Stomach trouble crops up for plenty of folks. Nausea, stomach pain, and even small ulcers can catch someone off guard, especially if they already have sensitive digestion. Think of someone juggling a couple pills for blood pressure, throwing this medicine into the mix, and suddenly they’re doubling over after dinner. Real stories, not rare ones.
Some individuals notice headaches or dizziness after starting a new antiplatelet like Ozagrel Methyl Ester. My neighbor reported difficulty focusing and a fuzzy feeling in her head when she began a similar drug. Anyone with a packed schedule, who drives, or cares for kids knows how disruptive that can be. Sometimes, these side effects ease up. At other times, they linger and make daily routines tougher.
It’s easy to brush off warnings about rare reactions until you see or experience them. Immune reactions—such as rashes, severe skin changes, or swelling—require quick action. Low platelet counts, called thrombocytopenia, can cause not just visible bruises but, in rare cases, dangerous internal bleeding. During my time volunteering at a stroke clinic, I saw a handful of patients with nosebleeds that wouldn’t stop and deep, dark bruises on their torso. Travel to the ER and lab tests confirmed their platelets had dropped dangerously.
Liver problems, signaled by yellowing skin or eyes, dark pee, or upper belly pain, also come up in rare cases. Anyone with a past history of liver trouble or who takes several medications needs to pay close attention. The liver processes almost everything we swallow, so it takes the hit if medicines clash.
Doctors and pharmacists play a big role in deciding if a medicine’s benefits outweigh the risks. But regular folks help by speaking up about symptoms and sticking with lab checkups. Blood tests show platelet counts and liver function. Open conversations with healthcare providers can stop trouble before it spirals. I always recommend keeping a simple notebook: write down dates for any odd symptoms—no detail is too small.
Taking steps to limit stomach upset—like having medicine with food or at certain times of day—may help. Other strategies can include switching to a similar agent if side effects feel unmanageable. Technology gives us access to digital health records, but good old-fashioned observation still helps most. Families and caregivers keep an eye out, noticing bruises or slow-to-heal cuts that patients often overlook.
Staying informed and watchful means fewer surprises and a safer medication journey. Not every bit of trouble becomes a crisis, but no one regrets catching a problem early. Balancing risks with rewards means embracing both medical advice and family wisdom—look out, ask questions, and act quickly when something feels off.
In the world of pharmaceuticals, taking shortcuts never flies. Every detail counts. Ozagrel Methyl Ester may not show up on pharmacy shelves the way over-the-counter painkillers do, but its journey from the bench to the bedside carries some heavy responsibility. Administered for platelet aggregation and blood clot prevention, this medication has life-saving potential. Simple mistakes, from the method of delivery to the setting in which dosing happens, can turn a helpful drug into a costly problem.
Ozagrel Methyl Ester works by targeting thromboxane production, an essential process in blood clotting. Directly injecting an incorrect dose or using an inappropriate route risks bleeding or the opposite–clot formation. My own experiences in hospital settings have highlighted the difference one detail can make. I remember watching nurses double-check the dilution concentration, call the pharmacy for clarity, and consult the latest protocols before starting an intravenous drip of such agents. Their stories always circle back to safety, guided by both hard lessons and institutional support for never working alone.
Most clinical guidelines recommend intravenous (IV) infusion for administering Ozagrel Methyl Ester. Oral dosing loses the battle against stomach acid, and the body can’t absorb enough active compound to get the necessary effect. IV infusions allow healthcare providers to manage the speed of delivery, making it easier to watch for side effects and tweak dosages. By tapping into the bloodstream directly, the entire dose reaches the intended site fast, which is vital when treating acute conditions like stroke or high-risk clot situations. I’ve seen doctors calmly explain to worried families the reason for the IV setup: it’s about real-time control in the moments that count.
No one-size-fits-all answer exists for dosing. Body weight, age, kidney and liver function all guide the calculation. In routine care, pharmacists and doctors work together, checking lab results and reviewing histories. Some patients need just a loading dose to kick-start the process; others require steady, longer infusions. The best teams stay in close contact, reviewing blood markers and clinical response at every stage. Skipping these checks leads to complications, and every chart error could send a patient down the wrong path.
The stakes of administration reach beyond individual skill. Training keeps practitioners up to date, but strong oversight systems add another layer of protection. Hospital protocols require pharmacists to sign off on every order. Nurses stick with checklists, monitoring heart rate, blood pressure, and labs through every drip change. In discussion with colleagues, I’ve heard stories about how these layers catch even minor oversights before harm can happen. Real safety comes from collective effort–day-in, day-out attention to the human being, not just the drug label.
New technology helps minimize error. Smart infusion pumps, electronic prescribing, and automated reminders take some burden off already busy staff. Data from recent studies suggest these tools drop medication error rates significantly. Investing here makes sense. But there’s still no substitute for thoughtful care. Clear communication, robust protocols, and regular training build a wall against mistakes. Every innovation, from a clever barcode scanner to a new online resource, deserves a seat at the table.
No patient should fear the cure more than the condition. Correct administration of Ozagrel Methyl Ester, grounded in scientific evidence and careful oversight, reflects deep respect for life on both sides of the syringe. Every safe, thoughtful dose speaks to the value of trust in medicine—not just between doctor and patient, but across the whole care team.
Each time a new medication catches attention, real conversations start about safety. With Ozagrel Methyl Ester, doctors and patients both want to check what risks could show up during treatment. Looking for good outcomes means weighing benefits against possible harm, especially for drugs designed to affect blood clotting. Ozagrel gets used as an antiplatelet drug, aiming to help with certain circulatory problems, especially for people facing a higher risk of blood clots.
Doctors feel cautious about giving Ozagrel Methyl Ester to certain individuals. Patients who’ve had bleeding problems need special attention because the medicine blocks platelet activity—our bodies rely on platelets to stop bleeding after injuries or surgery. Stories shared by medical professionals and patient community forums talk about cases where people with active peptic ulcers, recent strokes, or blood disorders got worse after starting treatment with strong antiplatelet drugs. Ozagrel adds to that warning list.
I remember working alongside a physician who stopped short of prescribing Ozagrel to a patient with chronic liver disease. The reason? Liver problems can magnify the drug’s effects and raise the chance of uncontrolled bleeding. Kidney issues also make Ozagrel less predictable. A person’s age, frailty, and overall health become part of the safety equation, as older adults face more risk. Every medical history tells its own story—some conditions call for stepping back instead of pushing forward with a new medication.
Side effects get most attention in clinics because they pop up in daily life. Ozagrel’s known side effects include headaches, nausea, skin reactions, and, most concerning, bleeding. There have been documented incidents of gastrointestinal bleeding, nosebleeds, and unusual bruising. People often underestimate how a small cut or fall might lead to significant problems if platelet function drops too far. Real cases show even minor injuries can become serious for someone on antiplatelet therapy.
Stories from hospitals reveal that regular blood tests and check-ups help spot complications early. Healthcare providers track blood counts and liver enzymes, not because they’re worried about statistics, but because each result matters for the person in front of them. Pharmacists and nurses play an important role in teaching patients the warning signs—such as dark stools, persistent nosebleeds, or unusual tiredness. All those signs should lead to a phone call or clinic visit, not another wait-and-see day at home.
Honest conversations between doctors and people receiving Ozagrel can clear up confusion. Some folks feel nervous, remembering negative media headlines about blood thinners. Yet research shows Ozagrel’s benefits for certain stroke and clot prevention cases if used responsibly. The important part comes from sharing medical records and updates, rather than cutting corners with disclosure. Medical teams should encourage questions. Patients have every right to know what to expect and how to reach help if things change fast.
Drug safety often relies more on real-life awareness than instructions in a package leaflet. Community pharmacists share careful reminders, families monitor for symptoms, and everyone pays attention for the early warning signs. By lifting stigma around health worries, more people will feel comfortable to speak up about side effects and let their doctors know if days don’t feel right after starting a new medication like Ozagrel Methyl Ester.
People ask a lot about mixing drugs. Ozagrel Methyl Ester isn’t a name you hear from ads on TV, but it matters to folks dealing with clotting issues. Once a doctor says, “Let’s try this for your blood,” the next worry is what happens if you’re already taking something else.
When you pile new medicine on top of heart pills, blood thinners, or just something for a headache, it’s not about hoping for the best. Ozagrel Methyl Ester blocks a step in the body that helps make clots. That’s the point—it can stop strokes and heart attacks if clots are a threat. The trouble comes when it teams up with other medicines that thin your blood, like warfarin or aspirin. Too much thinning, and you’re not protected. Instead, you’re vulnerable. Bleeding goes from rare to real risk. Even bruises from bumping a table can mean trouble, not to mention nosebleeds or blood in urine.
Doctors know this. Textbooks and real-life experience back it up. Mixing drugs that change how your blood clots isn’t just “something to check”; it’s in every guide for safe prescribing. Clinical guidelines draw from years of research. A study out of Japan in 2019 showed that Ozagrel combinations with other blood thinners made bleeding complications pop up twice as much compared to solo use. These aren’t numbers cooked up in a lab—they come from tracking actual patients after surgery, after strokes, and on long-term treatment.
Think about pharmacy trips. Most folks collect a bucket of pills: cholesterol meds, diabetes treatments, maybe some ibuprofen here and there. Real life does not mix well with spreadsheets. Ozagrel Methyl Ester rarely ends up taken by itself. Left hand doesn’t always know what the right hand is doing—two doctors, one phone call missed, and suddenly there’s a dangerous cocktail on the kitchen counter.
Some medicines just don’t get along. NSAIDs like naproxen, antiplatelet agents, and certain antibiotics can all twist the effects or boost the risk of side effects with Ozagrel Methyl Ester. These aren’t hidden dangers—labels and pharmacists flag them for a reason. I’ve seen people wind up with bleeding gums they thought were from brushing too hard, not realizing it was a quiet clash between prescriptions. Older folks, especially, have kidneys that don’t clear drugs as fast, which can turn smaller misjudgments into bigger problems.
No one expects patients to memorize every risk. That’s not a fair fight. The best fixes happen with clear conversation. Bring every pill bottle to the doctor, not just the one in question. Pharmacists scan for problems that computers miss. If a doctor suggests Ozagrel Methyl Ester, the next words out of your mouth should be, “Here’s my full medication list.” No shame, no embarrassment—these details might save you from nasty complications.
Education matters. Hospitals and clinics run programs so patients pick up on red flags: sudden bruising, headaches worse than normal, or blood in places it shouldn’t be. I’ve seen firsthand that catching those signs early keeps you out of the emergency room. Safety nets are a team job—doctor, pharmacist, patient. That’s how you keep Ozagrel Methyl Ester doing its job without unwanted company.
| Names | |
| Preferred IUPAC name | methyl (2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoate |
| Other names |
OKY-046 Ozagrel methyl ester Ozagrel methyl Methyl Ozagrel |
| Pronunciation | /ˈoʊzəˌɡrɛl ˈmɛθəl ˈɛstər/ |
| Identifiers | |
| CAS Number | 105462-38-6 |
| Beilstein Reference | 4708733 |
| ChEBI | CHEBI:78615 |
| ChEMBL | CHEMBL2106036 |
| ChemSpider | 21735812 |
| DrugBank | DB12624 |
| ECHA InfoCard | echa infocard 1008901 |
| Gmelin Reference | Gmelin Reference: 934422 |
| KEGG | C13523 |
| MeSH | D017347 |
| PubChem CID | 10184651 |
| RTECS number | GV9482000 |
| UNII | 9S8SMC7TP3 |
| UN number | UN3272 |
| CompTox Dashboard (EPA) | DTXSID8055476 |
| Properties | |
| Chemical formula | C14H13NO4 |
| Molar mass | 335.36 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.24 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.6 |
| Acidity (pKa) | 10.14 |
| Basicity (pKb) | 6.02 |
| Magnetic susceptibility (χ) | -51.2e-6 cm^3/mol |
| Refractive index (nD) | 1.577 |
| Viscosity | Viscous oil |
| Dipole moment | 4.11 D |
| Pharmacology | |
| ATC code | B01AC13 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | NFPA 704: 1-2-0 |
| Flash point | Flash point: 248.2°C |
| LD50 (median dose) | LD50: >2000 mg/kg (rat, oral) |
| NIOSH | NA |
| REL (Recommended) | 0.1-1 mg/kg |
| Related compounds | |
| Related compounds |
Ozagrel Ozagrel sodium |
